$-0.41
(Market cap
$96 Mln
Recently Viewed
Clear AllMarket cap
$96 Mln
Revenue (TTM)
$1 Mln
P/E Ratio
--
P/B Ratio
2.2
Div. Yield
0 %
Today’s Range
52 Week Range
Liquidity
Net Profit (TTM)
$0 Mln
ROE
-1.1 %
ROCE
-- %
Industry P/E
--
EV/EBITDA
-0.2
Debt to Equity
0
Book Value
$42.5
EPS
$-39
Face value
--
Shares outstanding
1,372,278
CFO
$-159.54 Mln
EBITDA
$-191.71 Mln
Net Profit
$-188.81 Mln
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Spruce Biosciences Inc (SPRB)
| -19.8 | 18.4 | -4.9 | 58,783.7 | 220.7 | 35.0 | -- |
|
BSE Sensex*
| -6.4 | 6.4 | -3.5 | 0.9 | 10.0 | 10.7 | 11.9 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2025
|
2024
|
2023
|
2022
|
2021
|
|---|---|---|---|---|---|
|
Spruce Biosciences Inc (SPRB)
| 20,640.5 | -85.4 | 167.0 | -75.4 | -81.7 |
|
S&P Small-Cap 600
| 4.0 | 7.0 | 13.9 | -17.4 | 25.3 |
|
BSE Sensex
| 9.1 | 8.1 | 18.7 | 4.4 | 22.0 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Spruce Biosciences Inc (SPRB)
|
69.9 | 96.5 | 0.0 | -39.0 | -5,069.7 | -109.2 | -- | 2.2 |
| 69.3 | 9,733.6 | 1,091.0 | 202.3 | 31.6 | 31.3 | 43.4 | 17.1 | |
| 66.1 | 8,216.2 | 88.0 | -785.0 | -808.1 | 197.5 | -- | 60.3 | |
| 43.6 | 11,658.3 | 2,320.1 | 782.6 | 39.0 | 35.5 | 16.1 | 5.3 | |
| 91.1 | 11,852.6 | 982.0 | -416.3 | -42.1 | 348.4 | -- | 55.7 | |
| 69.6 | 8,209.1 | 1,396.6 | 316.9 | 59.8 | 153.6 | 27.1 | 161.7 | |
| 527.1 | 12,204.5 | 958.4 | -288.3 | -27.8 | -42.5 | -- | 20.3 | |
| 528.4 | 14,867.3 | 2,530.2 | 451.1 | 21.3 | 70.2 | 34 | 32.4 | |
| 108.2 | 8,460.0 | 0.0 | -425.4 | -- | -36.7 | -- | 6.8 | |
| 342.6 | 9,538.9 | 0.0 | -303.3 | -- | -45.8 | -- | 10.9 |
Spruce Biosciences, Inc. is a biopharmaceutical company focused on developing and commercializing novel therapies for neurological disorders. The company develops TA-ERT, a fusion protein comprised of recombinant human alpha-N-acetylglucosaminidase,... which is an enzyme replacement therapy for patients with Sanfilippo Syndrome Type B. It also develops Tildacerfont for treating a highly debilitating mental disorder characterized by depressed mood with cognitive-affective and somatic changes, including anhedonia, weight alterations, and altered sleeping patterns. In addition, the company develops SPR202 for the treatment of Congenital Adrenal Hyperplasia (CAH), a chronic and potentially life-threatening rare disease with no cure. The company has a license agreement with Eli Lilly and Company to research, develop, and commercialize various pharmaceutical compounds. It also has a collaboration and license agreement with Kaken Pharmaceutical Co. Ltd. to develop, manufacture, and commercialize Tildacerfont for the treatment of CAH in Japan. Spruce Biosciences, Inc. was incorporated in 2014 and is headquartered in South San Francisco, California. Read more
Executive Chairman
Mr. Michael G. Grey
Executive Chairman
Mr. Michael G. Grey
Headquarters
South San Francisco, CA
Website
Our rating system has guided millions of investors in the past 20 years.
The share price of Spruce Biosciences Inc (SPRB) is $69.90 (NASDAQ) as of 20-Apr-2026 16:29 EDT. Spruce Biosciences Inc (SPRB) has given a return of 220.65% in the last 3 years.
Since, TTM earnings of Spruce Biosciences Inc (SPRB) is negative, P/E ratio is not available.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2025
|
-2.24
|
2.05
|
|
2024
|
-0.01
|
0.01
|
|
2023
|
-0.06
|
0.04
|
|
2022
|
--
|
--
|
|
2021
|
--
|
--
|
The 52-week high and low of Spruce Biosciences Inc (SPRB) are Rs 104.46 and Rs 0.06 as of 21-Apr-2026.
Spruce Biosciences Inc (SPRB) has a market capitalisation of $ 96 Mln as on 17-Apr-2026. As per SEBI classification, it is a Small Cap company.
Before investing in Spruce Biosciences Inc (SPRB), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.